All In Biotech

Drug Trial Radar · NCT07540988

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

A Double-blind, Randomized, Placebo-controlled Trial Investigating the Efficacy and Safety of Nerandomilast Over at Least 52 Weeks in Patients With Fibrosing Interstitial Lung Disease at Risk for Disease Progression (FIBRONEER-ACT)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 466 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

466

Planned (sponsor's estimate)

Start

Sep 17, 2026

Primary completion

Dec 5, 2028

Study completion Dec 12, 2028

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Apr 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are at risk of developing progressive pulmonary fibrosis (PPF). The purpose of this study is to find out whether a medicine called nerandomilast helps people with fibrosing interstitial lung disease who may be at risk for their disease getting worse. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Nerandomilast is a type of medicine that may help reduce lung function decline and slow disease progression. Participants are in the study for up to about 2 years and 4 months. During this time, they visit the study site regularly. Doctors regularly test lung function using methods like spirometry to measure forced vital capacity (FVC, maximum amount of air a participant can blow out after taking a deep breath) and DLCO (diffusing capacity of the lungs for carbon monoxide; it estimates how well oxygen moves from the lungs into the blood). Additionally, high-resolution computed tomography (HRCT) is performed to monitor how the lung condition is changing over time. The results are compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Interstitial Lung Diseases

Interventions

  • NerandomilastDrug

    Nerandomilast

  • Placebo matching nerandomilastDrug

    Placebo matching nerandomilast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change from baseline in forced vital capacity (FVC) (mL) at Week 52Time frame: at baseline, at week 52

Locations

162 sites in 20 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Not yet recruiting

  • University of Southern California

    Los Angeles, California · Not yet recruiting

  • Newport Native MD, Inc

    Newport Beach, California · Not yet recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Not yet recruiting

  • Clinical Research Specialists LLC - Kissimmee

    Kissimmee, Florida · Not yet recruiting

  • Lakeland Regional Medical Center - Lakeland

    Lakeland, Florida · Not yet recruiting

  • Advanced Pulmonary Research Institute

    Loxahatchee Groves, Florida · Not yet recruiting

  • Essence MD Research

    Naples, Florida · Not yet recruiting

  • Avanza Medical Research Center

    Pensacola, Florida · Not yet recruiting

  • Coastal Pulmonary & Critical Care

    St. Petersburg, Florida · Not yet recruiting

  • Cleveland Clinic Florida

    Weston, Florida · Not yet recruiting

  • Indiana University Health Enterprise Clinical Research Operation

    Indianapolis, Indiana · Not yet recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Not yet recruiting

  • University of Michigan

    Ann Arbor, Michigan · Not yet recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Not yet recruiting

  • Mayo Clinic, Rochester

    Rochester, Minnesota · Not yet recruiting

  • Henderson Clinical Trials

    Henderson, Nevada · Not yet recruiting

  • Weill Cornell Medicine-New York-60569

    New York, New York · Not yet recruiting

  • New York Presbyterian Hospital -Columbia University

    New York, New York · Not yet recruiting

  • Coastal Carolina Health Care, P.A. Pulmonary and Sleep Medicine

    New Bern, North Carolina · Not yet recruiting

  • Southeastern Research Center-Winston-Salem-61365

    Winston-Salem, North Carolina · Not yet recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Not yet recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Not yet recruiting

  • Temple University

    Philadelphia, Pennsylvania · Not yet recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Lowcountry Lung and Critical Care

    Charleston, South Carolina · Not yet recruiting

  • Baylor University Medical Center

    Dallas, Texas · Not yet recruiting

  • Metroplex Pulmonary & Sleep Center

    McKinney, Texas · Not yet recruiting

  • UT Health San Antonio

    San Antonio, Texas · Not yet recruiting

  • University of Utah Health Sciences Center

    Salt Lake City, Utah · Not yet recruiting

  • Instituto de Medicina Respiratoria (IMeR)

    Alberdi Sur, Argentina · Not yet recruiting

  • Fundacion NIBA Neurologia Infantil Buenos Aires

    CABA, Argentina · Not yet recruiting

  • Consultorios Medicos del Buen Ayre

    Capital Federal, Argentina · Not yet recruiting

  • Hospital Aleman

    Capital Federal, Argentina · Not yet recruiting

  • Instituto Ave Pulmo - Fundacion Enfisema

    Mar del Plata, Argentina · Not yet recruiting

  • INSARES

    Mendoza, Argentina · Not yet recruiting

  • Fundacion Innovaciencia

    Rosario, Argentina · Not yet recruiting

  • Royal Prince Alfred Hospital

    Camperdown, Sydney, New South Wales, Australia · Not yet recruiting

  • Lung Research Queensland

    Chermside, Queensland, Australia · Recruiting

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia · Not yet recruiting

Showing 40 of 162 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.